Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 8/20 | 0.42 |
| ▸ | ADRB1 | P08588 | 5/20 | 0.42 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.38 |
| ▸ | DRD1 | P21728 | 2/20 | 0.38 |
| ▸ | DRD4 | P21917 | 2/20 | 0.38 |
| ▸ | DRD3 | P35462 | 2/20 | 0.38 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.37 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | SYK | P43405 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL963630 | 1.00 | ADRB2 (0.42) | ADRB2ADRB1ADRB3MAPTL3MBTL1 | |
| SCHEMBL963633 | 1.00 | ADRB2 (0.42) | ADRB2ADRB1ADRB3MAPTL3MBTL1 | |
| SCHEMBL5822288 | 0.96 | ADRB2 (0.40) | ADRB2ADRB1ADRB3MAPTL3MBTL1 | |
| SCHEMBL5763148 | 0.93 | ADRB2 (0.42) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL5763122 | 0.93 | ADRB2 (0.42) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL17633021 | 0.93 | ADRB2 (0.42) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL28423946 | 0.91 | ADRB2 (0.42) | ADRB2ADRB1ADRB3MAPTDRD2 | |
| SCHEMBL28423949 | 0.91 | ADRB2 (0.42) | ADRB2ADRB1ADRB3MAPTDRD2 | |
| SCHEMBL28423974 | 0.90 | ADRB2 (0.42) | ADRB2ADRB1DRD2DRD1DRD4 | |
| SCHEMBL28423971 | 0.90 | ADRB2 (0.42) | ADRB2ADRB1DRD2DRD1DRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8008278-B2 | Diarylmethyl and related compounds | THERAVANCE, INC. (US) | 2011-08-30 | — | — | US | disclosed |
| US-20110015152-A1 | DIARYLMETHYL AND RELATED COMPOUNDS | THERAVANCE, INC. (US) | 2011-01-20 | — | — | US | disclosed |
| EP-1615889-B1 | BIPHENYL DERIVATIVES HAVING BETA2 ADRENERGIC RECEPTOR AGONIST AND MUSCARINIC RECEPTOR ANTAGONIST ACTIVITY | THERAVANCE INC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-7521561-B2 | Biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenyl-carbamoyl)ethyl]piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, asthma | THERAVANCE, INC. (US) | 2009-04-21 | — | — | US | disclosed |
| US-7345175-B2 | Biphenyl derivatives | THERAVANCE, INC. (US) | 2008-03-18 | — | — | US | disclosed |
| US-20060229334-A1 | Biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenyl-carbamoyl)ethyl]piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, asthma | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-10-12 | — | — | US | disclosed |
| US-20060223858-A1 | Biphenyl derivatives | THERAVANCE BIOPHARMA R&D IP, LLC | 2006-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060223858-A1 | Biphenyl derivatives | ADRB1, ADRB2, ADRB3 | ADRB2 2/4885ADRB1 1/4885ADRB3 3/4885 |
| US-20110015152-A1 | DIARYLMETHYL AND RELATED COMPOUNDS | ADRB2, ADRB1, ADRA2B | ADRB2 1/4885ADRB1 2/4885ADRB3 4/4885 |
| US-20060229334-A1 | Biphenyl-2-ylcarbamic acid 1-[2-(2-chloro-4-{[(R)-2-hydroxy-2-(8-hydroxy-2-oxo-1,2-dihydroquinolin-5-yl)ethylamino]methyl}-5-methoxyphenyl-carbamoyl)ethyl]piperidin-4-yl ester; beta 2 adrenergic receptor agonist and muscarinic receptor antagonist; bronchodilator agent; pulmonary disorders, asthma | ADRB2, ADRA2B, ADRB1 | ADRB2 1/4885ADRB1 3/4885ADRB3 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.